<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>82</patient-age><report-id>PHHY2012CO113464</report-id><gender>female</gender><reactions><reaction>Pelvic fracture</reaction><reaction>Fractures (unspecified areas)</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>ACLASTA</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>BIOCALCIUM</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>CALCIUM</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Osteoporosis</indication></indications><outcomes/><country>Colombia</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053161_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134146</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2012CO113464</safetyreportid>
		<primarysourcecountry>CO</primarysourcecountry>
		<occurcountry>CO</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-10</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-12-06</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-06</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012CO113464</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>CO</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>MM</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19301127</patientbirthdate>
			<patientweight>62</patientweight>
			<patientheight>156</patientheight>
			<patientsex code="2">Female</patientsex>
			<reaction>
				<primarysourcereaction>Pelvic fracture</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Pelvic fracture</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Pelvic fracture</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120916</reactionstartdate>
				<reactionfirsttime>362</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Fractures (unspecified areas)</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Fracture</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Fracture</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>ACLASTA</medicinalproduct>
				<obtaindrugcountry>CO</obtaindrugcountry>
				<drugauthorizationnumb>21-817</drugauthorizationnumb>
				<drugauthorizationcountry>CO</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugdosagetext>UNK UKN, annual</drugdosagetext>
				<drugdosageform normalized="solution for injection">Solution For Injection</drugdosageform>
				<drugadministrationroute code="042">Intravenous (not otherwise specified)</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Osteoporosis</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-09-21</drugstartdate>
				<drugstartperiod>362</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>ZOLEDRONATE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Fracture</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Fracture</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pelvic fracture</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pelvic fracture</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>BIOCALCIUM</medicinalproduct>
				<obtaindrugcountry>CO</obtaindrugcountry>
				<drugauthorizationcountry>CO</drugauthorizationcountry>
				<actiondrug code="4">Dose not changed</actiondrug>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>CALCIUM</medicinalproduct>
				<obtaindrugcountry>CO</obtaindrugcountry>
				<drugauthorizationcountry>CO</drugauthorizationcountry>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>CALCIUM</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012CO113464, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report received from consumer (patient’s relative) via patient support program “Aclasta V+S” on 06 Dec 2012. This report refers to an 81-year old female patient (ID: 2971). Concomitant medications included Biocalcium and <Semaphore x="287292" class="Medicine" value="Calcium" score="0.49" ID="240008">calcium</Semaphore>. <Semaphore x="2394286" class="Procedure" value="Pharmacotherapy" score="1.00" ID="C15986">Treatment with these medications </Semaphore>continued. The patient received Aclasta (<Semaphore x="1384774" class="Medicine" value="zoledronic acid" score="0.49" ID="274011">zoledronic <Semaphore x="2147465" class="Procedure" value="Lysergide Measurement" score="1.00" ID="C75354">acid</Semaphore></Semaphore>) for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of <Semaphore x="2351610" class="Procedure" value="Osteoporosis Management" score="1.00" ID="C62745">osteoporosis </Semaphore>at an unknown dose IV, annual on 21 Sep 2011. On 16 Sep 2012, patient experienced <Semaphore x="2383651" class="AnatomicStructure" value="Pelvis" score="1.00" ID="C12767">pelvis </Semaphore><Semaphore x="1946531" class="Procedure" value="Fracture Fixation" score="1.00" ID="C52008">fracture </Semaphore>and <Semaphore x="1946531" class="Procedure" value="Fracture Fixation" score="1.00" ID="C52008">fractures </Semaphore>(unspecified areas). During 2012, patient also experienced <Semaphore x="1946531" class="Procedure" value="Fracture Fixation" score="1.00" ID="C52008">fractures </Semaphore>(unspecified areas). The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>was unknown. <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">Treatment </Semaphore>with Aclasta continued. The events were assessed as serious and not suspected to be related to <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with Aclasta.</narrativeincludeclinical>
				<sendercomment>Based on review of available reported data does not allow for a proper causality assessment. Reported events (pelvic fracture and fracture) are not assessable with the current data. Pending any new medical information.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>